{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-058864","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2026-08-25T20:06:36+00:00","discovered_at":"2026-08-25T20:08:00.762738+00:00","generated_at":"2026-08-25T20:08:28.935835+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Jazz Pharma gets FDA approval for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma","bullets":["FDA approved Ziihera (zanidatamab-hrii) plus Tevimbra (tislelizumab-jsgr) and chemo for all HER2+ GEA (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status.","Second approval: Ziihera plus chemo for HER2+ IHC 3+ GEA; based on Phase 3 HERIZON-GEA-01 trial.","Trial showed 35% PFS risk reduction (12.4 vs 8.1 months) and 28% OS risk reduction (26.4 vs 19.2 months) vs trastuzumab plus chemo.","Jazz hosts investor webcast Aug 25, 4:30pm ET; Ziihera is first bispecific HER2-targeted antibody plus PD-1 inhibitor approved in this setting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-058864","json":"https://secwatch.observer/filing/0001628280-26-058864.json","markdown":"https://secwatch.observer/filing/0001628280-26-058864.md","text":"https://secwatch.observer/filing/0001628280-26-058864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/0001628280-26-058864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/jazz-20260825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-25T20:08:28.935835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}